Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expec ...

Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 -- SLS009: Full Topline Phase 2 Data ...

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

Introduction: Progressing myelodysplastic syndrome (MDS) into acute myeloid leukemia (AML) is an indication for hypomethylating therapy (HMA, 5-Azacytidine (AZA)) and a BCL2 inhibitor (Venetoclax, VEN ...